Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes.

Curriculum Vitae Scott J. Myers, Ph.D. ADDRESS: 1510 Clifton Rd NW, Atlanta, GA, 30322; Tel: (404)337-0618 (C), 404-727-5968 (Lab) CURRENT POSITIONS: 2019-2024 Instructor, Department of Pharmacology and Chemical Biology, Emory University, SOM 2016-2024 Associate Director, CFERV, Emory Univ, SOM PAST POSITIONS: 2016-2019 Associate Scientist, Department of Pharmacology, Emory University, SOM 2006-2016 Director, Drug Discovery, NeurOp, Inc., Atlanta, GA EDUCATION AND POSTDOC TRAINING: 2005-2006 Postdoctoral Fellow, Dr. Gwenn Garden Lab, M.D. Univ. Washington, Seattle 2000-2004 Postdoctoral Fellow, Dr. William A. Catterall Lab, Univ. Washington, Seattle 1999 Postdoctoral Fellow, Dr. Ray Dingledine Lab, Emory University, SOM 1998 Ph.D. Pharmacology, University of North Carolina at Chapel Hill 1986 B.S. Cell Biology, University of Kansas PROFESSIONAL MEMBERSHIP: Society for Neuroscience, American Society of Human Genetics HONORS/AWARDS: 2010, Startup of the Year Award, NeurOp, Inc.; 2000-01, Molecular Neurobiology Fellowship, Univ. of Washington; 1997-98, NIH National Research Service Award, Emory University; 1994, Excellence in Research Award, the J. David Gladstone Institutes, SF, CA; 1985, Honors Research Award, University of Kansas JOURNAL REVIEW: Journal of Biological Chemistry; Journal of Neurochemistry; Pharmacological Reports; Neurotherapeutics; Reviews in the Neurosciences GRANT REVIEWs: 2011 - NIMH RAPID, Technical Evaluation Review Panel INVITED PRESENTATIONS: 2019 -GRIN2B Europe Symposium; 2014-Biotech Showcase, SF, CA; 2007 -Southeast Pharmacology Society LECTURES/TEACHING: Local Anesthetics Lect., Allied Health and M2 Neuroscience (Emory, 4 yrs) SCIENTIST TRAINING/SUPERVISION: 2006-present at NeurOp and Emory: at Emory- Dr. Wei Han, Chongqing Medical Univ. Children Hospital, China; Dr. Lingling Xie, Chongqing Medical Univ. Children Hospital, China; Stephanie Ross, MS, Vincent Peterson, MS; Sukhan Kim; James P. Allen, Rebecca Bui, Gil Shaulsky, Courtney Ning, Brantley Holland, Minwoo Choi, Ian Hwang, Andrew Nie, Ian Huang, Lynnea Harris, Duke McDaniels, Minwoo Choi, Kelsey Nocilla, Rehan Sheikh; at NeurOp Dr. Hasan Irier; Dr. Lixia Zhao; Dr. Julie Bennett-Desmelik; Dr. Kamalesh Ruppa; Zack Dentmon, NeurOp; Polina Lyubolslavsky, NeurOp. PAST and CURRENT RESEARCH SUPPORT: 1. 2006 2R44 NS049666-02A1 Myers (PI) $1,500,000 09/01/06 – 08/31/09 Lead optimization of NR2B selective antagonists with high pH dependence. NIH/NINDS 2. 2010 BMS-NeurOp Collaboration Myers (PI) $3,500,000 12/22/09 – 12/21/12 Lead optimization of NR2B selective antagonist for use in treatment resistant BMS 3. 2011 4U44NS071657-01A1 Myers (coPI) Koszalka (PI) $3,000,000 02/28/11 – 03/01/15 Select a candidate molecule suitable for clinical development; file an IND. NIH/NINDS 4. 2012 2R43MH096363-01 Myers (PI) $700,711 04/01/12 – 03/31/14 Lead optimization of GluN2C/2D modulators for schizophrenia/cognitive disorders. NIH/NIMH 5. 2014-15 Janssen-NeurOp Collab Myers (PI) $500,000 09/05/14 – 09/03/15 Lead Optimization of GluN2C and GluN2D selective modulators. Janssen Pharma. 6. 2014 1R41AG048723-01 Myers (coPI) w/ Johnson (coPI) $219,338 09/15/14 –08/31/15 NMDA Receptor Subtype Selective Modulators as Alzheimer’s Disease Therapeutics. NIH/NIA 7. 2021 GRA.VL21.C3 Myers (PI) $ 25,000 11/08/21 –06/30/22 Agrithera-Cannabidiol Prodrugs as Therapies for Pain, Anxiety, and Seizures. Georgia GRA 8. 2021 GRA.VL21.C3 Myers (PI) $ 50,000 1/08/23 –10/31/23 Agrithera-Cannabidiol Prodrugs as Therapies for Pain, Anxiety, and Seizures. Georgia GRA 9. 2022-23 SRA from GRIN Therapeutics Myers (PI) $238,936 04/01/22 –10/31/23 Functional Evaluation and Radiprodil Inhibition of Rare GRIN Variants GRIN Therapeutics 10. 2021-24 1R21AG072142-01 Myers (PI) $425,269 05/15/21 –05/30/24 Use of Bioinformatics and Genetics to Identify a New Class of Drugs. NIH/NIA PUBLICATIONS: (Most recent listed first) 1 Distances from ligands as main predictive features for pathogenicity and functional effect of variants in NMDA receptors. Montanucci L, Brünger T, Bhattarai N, Boßelmann CM, Kim S, Allen JP, Zhang J, Klöckner C, Fariselli P, May P, Lemke JR, Myers SJ, Yuan H, Traynelis SF, Lal D. medRxiv [Preprint]. 2024 May 7:2024.05.06.24306939. doi: 10.1101/2024.05.06.24306939. PMID: 38766179 2 De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor. Xu Y, Song R, Perszyk RE, Chen W, Kim S, Park KL, Allen JP, Nocilla KA, Zhang J, XiangWei W, Tankovic A, McDaniels ED, Sheikh R, Mizu RK, Karamchandani MM, Hu C, Kusumoto H, Pecha J, Cappuccio G, Gaitanis J, Sullivan J, Shashi V, Petrovski S, Jauss RT, Lee HK, Bozarth X, Lynch DR, Helbig I, Pierson TM, Boerkoel CF, Myers SJ, Lemke JR, Benke TA, Yuan H, Traynelis SF. Cell Mol Life Sci. 2024 Mar 28;81(1):153. doi: 10.1007/s00018-023-05069-z. PMID: 38538865 3 Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants. Allen JP, Garber KB, Perszyk R, Khayat CT, Kell SA, Kaneko M, Quindipan C, Saitta S, Ladda RL, Hewson S, Inbar-Feigenberg M, Prasad C, Prasad AN, Olewiler L, Mu W, Rosenthal LS, Scala M, Striano P, Zara F, McCullock TW, Jauss RT, Lemke JR, MacLean DM, Zhu C, Yuan H, Myers SJ, Traynelis SF. Hum Mol Genet. 2024 Feb 1;33(4):355-373. doi: 10.1093/hmg/ddad188. PMID: 37944084 4 A frameshift variant of GluN2A identified in an epilepsy patient results in NMDA receptor mistargeting. Vieira MM, Peng S, Won S, Hong E, Inati SK, Thurm A, Thiam AH, Kim S, Myers SJ, Badger JD 2nd, Traynelis SF, Lu W, Roche KW. J Neurosci. 2024 Jan 24;44(4):e0557232023. doi: 10.1523/JNEUROSCI.0557-23.2023. PMID: 38050135 5 Clinical and functional consequences of GRIA variants in patients with neurological diseases. XiangWei W, Perszyk RE, Liu N, Xu Y, Bhattacharya S, Shaulsky GH, Smith-Hicks C, Fatemi A, Fry AE, Chandler K, Wang T, Vogt J, Cohen JS, Paciorkowski AR, Poduri A, Zhang Y, Wang S, Wang Y, Zhai Q, Fang F, Leng J, Garber K, Myers SJ, Jauss RT, Park KL, Benke TA, Lemke JR, Yuan H, Jiang Y, Traynelis SF. Cell Mol Life Sci. 2023 Nov 3;80(11):345. doi: 10.1007/s00018-023-04991-6. PMID: 37921875 6 Classification of missense variants in the N-methyl-D-aspartate receptor GRIN gene family as gain- or loss-offunction. Myers SJ, Yuan H, Perszyk RE, Zhang J, Kim S, Nocilla KA, Allen JP, Bain JM, Lemke JR, Lal D, Benke TA, Traynelis SF. Hum Mol Genet. 2023 Sep 16;32(19):2857-2871. doi: 10.1093/hmg/ddad104. 2 PMID: 37369021 7 Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model. Harris LD, Regan MC, Myers SJ, Nocilla KA, Akins NS, Tahirovic YA, Wilson LJ, Dingledine R, Furukawa H, Traynelis SF, Liotta DC. ACS Chem Neurosci. 2023 Mar 1;14(5):917-935. doi: 10.1021/acschemneuro.2c00779. Epub 2023 Feb 13. PMID: 36779874 8 Intrathecal magnesium delivery for Mg++-insensitive NMDA receptor activity due to GRIN1 mutation. Lewis SA, Shetty S, Gamble S, Heim J, Zhao N, Stitt G, Pankratz M, Mangum T, Marku I, Rosenberg RB, Wilfong AA, Fahey MC, Kim S, Myers SJ, Appavu B, Kruer MC. Orphanet J Rare Dis. 2023 Aug 3;18(1):225. doi: 10.1186/s13023-023-02756-9. PMID: 37537625 9 Functional effects of disease-associated variants reveal that the S1-M1 linker of the NMDA receptor critically controls channel opening. Xie LL, McDaniel MJ, Perszyk RE, Kim S, Cappuccio G, Shapiro KA, MunozCabello B, Sanchez-Lara PA, Grand K, Nocilla KA, Sheikh R, Dulcet LA, Romano R, Pierson TM, Yuan H, Myers SJ, Traynelis SF. Cell Mol Life Sci. 2023 Mar 31;80(4):110. doi: 10.1007/s00018-023-04705-y. PMID: 37000222 10 Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions. Tang W, Beckley JT, Zhang J, Song R, Xu Y, Kim S, Quirk MC, Robichaud AJ, Diaz ES, Myers SJ, Doherty JJ, Ackley MA, Traynelis SF, Yuan H. Cell Mol Life Sci. 2023 Jan 16;80(2):42. doi: 10.1007/s00018-022-04667-7. PMID: 36645496 11 Compound-heterozygous GRIN2A null variants associated with severe developmental and epileptic encephalopathy. Strehlow V, Rieubland C, Gallati S, Kim S, Myers SJ, Peterson V, Ramsey AJ, Teuscher DD, Traynelis SF, Lemke JR. Epilepsia. 2022 Oct;63(10):e132-e137. doi: 10.1111/epi.17394. Epub 2022 Aug 30. PMID: 35983985 12 Overlapping cortical malformations in patients with pathogenic variants in GRIN1 and GRIN2B. Brock S, Laquerriere A, Marguet F, Myers SJ, Hongjie Y, Baralle D, Vanderhasselt T, Stouffs K, Keymolen K, Kim S, Allen J, Shaulsky G, Chelly J, Marcorelle P, Aziza J, Villard L, Sacaze E, de Wit MCY, Wilke M, Mancini GMS, Hehr U, Lim D, Mansour S, Traynelis SF, Beneteau C, Denis-Musquer M, Jansen AC, Fry AE, Bahi-Buisson NJ Med Genet. 2022 Apr 7:jmedgenet-2021-107971. doi: 10.1136/jmedgenet-2021-107971. Online ahead of print. PMID: 35393335 13 Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric NMethyl-D-Aspartate Receptors. Han W, Yuan H, Allen JP, Kim S, Shaulsky GH, Perszyk RE, Traynelis SF, Myers SJ. J Pharmacol Exp Ther. 2022 Apr;381(1):54-66. doi: 10.1124/jpet.121.001000. Epub 2022 Feb 2. PMID: 35110392 14 A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use. Myers SJ, Ruppa KP, Wilson LJ, Tahirovic YA, Lyuboslavsky P, Menaldino DS, Dentmon ZW, Koszalka GW, Zaczek R, Dingledine RJ, Traynelis SF, Liotta DC. J Pharmacol Exp Ther. 2021 Oct;379(1):41-52. doi: 3 10.1124/jpet.120.000370. Epub 2021 Sep 7. PMID: 34493631 15 A de novo GRIN1 Variant Associated With Myoclonus and Developmental Delay: From Molecular Mechanism to Rescue Pharmacology. Zhang J, Tang W, Bhatia NK, Xu Y, Paudyal N, Liu D, Kim S, Song R, XiangWei W, Shaulsky G, Myers SJ, Dobyns W, Jayaraman V, Traynelis SF, Yuan H, Bozarth X. Front Genet. 2021 Aug 3;12:694312. doi: 10.3389/fgene.2021.694312. eCollection 2021. PMID: 34413877 16 Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Amador A, Bostick CD, Olson H, Peters J, Camp CR, Krizay D, Chen W, Han W, Tang W, Kanber A, Kim S, Teoh J, Sah M, Petri S, Paek H, Kim A, Lutz CM, Yang M, Myers SJ, Bhattacharya S, Yuan H, Goldstein DB, Poduri A, Boland MJ, Traynelis SF, Frankel WN. Brain. 2020 Jul 1;143(7):2039-2057. doi: 10.1093/brain/awaa147. PMID: 32577763 17 Hodgkin-Huxley-Katz Prize Lecture: Genetic and pharmacological control of glutamate receptor channel through a highly conserved gating motif. Perszyk RE, Myers SJ, Yuan H, Gibb AJ, Furukawa H, Sobolevsky AI, Traynelis SF. J Physiol. 2020 Aug;598(15):3071-3083. doi: 10.1113/JP278086. Epub 2020 Jun 15. PMID: 32468591 18 Negative allosteric modulation of GluN1/GluN3 NMDA receptors. Zhu Z, Yi F, Epplin MP, Liu D, Summer SL, Mizu R, Shaulsky G, XiangWei W, Tang W, Burger PB, Menaldino DS, Myers SJ, Liotta DC, Hansen KB, Yuan H, Traynelis SF. Neuropharmacology. 2020 Oct 1;176:108117. doi: 10.1016/j.neuropharm.2020.108117. Epub 2020 May 7. PMID: 32389749 19 The GRIA3 c.2477G > A Variant Causes an Exaggerated Startle Reflex, Chorea, and Multifocal Myoclonus. Piard J, Béreau M, XiangWei W, Wirth T, Amsallem D, Buisson L, Richard P, Liu N, Xu Y, Myers SJ, Traynelis SF, Chelly J, Anheim M, Raynaud M, Maldergem LV, Yuan H. Mov Disord. 2020 Jul;35(7):1224-1232. doi: 10.1002/mds.28058. Epub 2020 May 5. PMID: 32369665 20 Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. Myers SJ, Yuan H, Kang JQ, Tan FCK, Traynelis SF, Low CM. F1000Res. 2019 Nov 20;8:F1000 Faculty Rev-1940. doi: 10.12688/f1000research.18949.1. eCollection 2019. PMID: 31807283 Review. 21 Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy. XiangWei W, Kannan V, Xu Y, Kosobucki GJ, Schulien AJ, Kusumoto H, Moufawad El Achkar C, Bhattacharya S, Lesca G, Nguyen S, Helbig KL, Cuisset JM, Fenger CD, Marjanovic D, Schuler E, Wu Y, Bao X, Zhang Y, Dirkx N, Schoonjans AS, Syrbe S, Myers SJ, Poduri A, Aizenman E, Traynelis SF, Lemke JR, Yuan H, Jiang Y. Brain. 2019 Oct 1;142(10):3009-3027. doi: 10.1093/brain/awz232. PMID: 31504254 22 De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases. Li J, Zhang J, Tang W, Mizu RK, Kusumoto H, XiangWei W, Xu Y, Chen W, Amin JB, Hu C, Kannan V, Keller SR, Wilcox WR, Lemke JR, Myers SJ, Swanger SA, Wollmuth LP, Petrovski S, Traynelis SF, Yuan H. Hum Mutat. 2019 Dec;40(12):2393-2413. doi: 10.1002/humu.23895. Epub 2019 Sep 10. PMID: 31429998 23 4 Di-aryl Sulfonamide Motif Adds π-Stacking Bulk in Negative Allosteric Modulators of the NMDA Receptor. Summer SL, Kell SA, Zhu Z, Moore R, Liotta DC, Myers SJ, Koszalka GW, Traynelis SF, Menaldino DS. ACS Med Chem Lett. 2019 Jan 4;10(3):248-254. doi: 10.1021/acsmedchemlett.8b00395. eCollection 2019 Mar 14. PMID: 30891121 24 Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD. Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22. PMID: 30796190 25 Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B0518) for GluN2B Subunit in the Brain. Fu H, Tang W, Chen Z, Belov VV, Zhang G, Shao T, Zhang X, Yu Q, Rong J, Deng X, Han W, Myers SJ, Giffenig P, Wang L, Josephson L, Shao Y, Davenport AT, Daunais JB, Papisov M, Yuan H, Li Z, Traynelis SF, Liang SH. ACS Chem Neurosci. 2019 May 15;10(5):2263-2275. doi: 10.1021/acschemneuro.8b00591. Epub 2019 Feb 27. PMID: 30698943 26 Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. Regan MC, Zhu Z, Yuan H, Myers SJ, Menaldino DS, Tahirovic YA, Liotta DC, Traynelis SF, Furukawa H. Nat Commun. 2019 Jan 18;10(1):321. doi: 10.1038/s41467-019-08291-1. PMID: 30659174 27 A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder. Fernández-Marmiesse A, Kusumoto H, Rekarte S, Roca I, Zhang J, Myers SJ, Traynelis SF, Couce ML, Gutierrez-Solana L, Yuan H. Mov Disord. 2018 Jul;33(6):992-999. doi: 10.1002/mds.27315. Epub 2018 Apr 11. PMID: 29644724 28 A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons. Swanger SA, Vance KM, Acker TM, Zimmerman SS, DiRaddo JO, Myers SJ, Bundgaard C, Mosley CA, Summer SL, Menaldino DS, Jensen HS, Liotta DC, Traynelis SF. ACS Chem Neurosci. 2018 Feb 21;9(2):306-319. doi: 10.1021/acschemneuro.7b00329. Epub 2017 Nov 2. PMID: 29043770 29 Human GRIN2B variants in neurodevelopmental disorders. Hu C, Chen W, Myers SJ, Yuan H, Traynelis SF. J Pharmacol Sci. 2016 Oct;132(2):115-121. doi: 10.1016/j.jphs.2016.10.002. Epub 2016 Oct 19. PMID: 27818011 Review. 30 Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, Wilson LJ, Liotta DC, Snyder JP, Traynelis SF. Neuron. 2015 Mar 18;85(6):1305-1318. doi: 10.1016/j.neuron.2015.02.008. Epub 2015 Feb 26. PMID: 25728572 31 pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. Wang H, James ML, Venkatraman TN, Wilson LJ, Lyuboslavsky P, Myers SJ, Lascola CD, Laskowitz DT Neurocrit Care. 2014 Feb;20(1):119-31. doi: 10.1007/s12028-013-9944-9. PMID: 24420693 32 5 Transcription factor p53 influences microglial activation phenotype. Jayadev S, Nesser NK, Hopkins S, Myers SJ, Case A, Lee RJ, Seaburg LA, Uo T, Murphy SP, Morrison RS, Garden GA. Glia. 2011 Oct;59(10):140213. doi: 10.1002/glia.21178. Epub 2011 May 19. PMID: 21598312 33 Glutamate receptor ion channels: structure, regulation, and function. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. PMID: 20716669 Review. 34 Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SF, Liotta DC. Bioorg Med Chem. 2009 Sep 1;17(17):6463-80. doi: 10.1016/j.bmc.2009.05.085. Epub 2009 Jul 5. PMID: 19648014 35 Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP. J Med Chem. 2008 Sep 25;51(18):5506-21. doi: 10.1021/jm8002153. PMID: 18800760 36 Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site. Yokoyama CT, Myers SJ, Fu J, Mockus SM, Scheuer T, Catterall WA. Mol Cell Neurosci. 2005 Jan;28(1):1-17. doi: 10.1016/j.mcn.2004.08.019. PMID: 15607937 37 Inhibition of glutamate receptor 2 translation by a polymorphic repeat sequence in the 5'-untranslated leaders. Myers SJ, Huang Y, Genetta T, Dingledine R. J Neurosci. 2004 Apr 7;24(14):3489-99. doi: 10.1523/JNEUROSCI.4127-03.2004. PMID: 15071096 38 Activity of the rat GluR4 promoter in transfected cortical neurons and glia. Borges K, Myers SJ, Zhang S, Dingledine R. J Neurochem. 2003 Sep;86(5):1162-73. doi: 10.1046/j.1471-4159.2003.01926.x. PMID: 12911624 39 Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Huang Y, Myers SJ, Dingledine R. Nat Neurosci. 1999 Oct;2(10):867-72. doi: 10.1038/13165. PMID: 10491605 40 Genetic regulation of glutamate receptor ion channels. Myers SJ, Dingledine R, Borges K. Annu Rev Pharmacol Toxicol. 1999;39:221-41. doi: 10.1146/annurev.pharmtox.39.1.221. PMID: 10331083 Review. 41 Transcriptional regulation of the GluR2 gene: neural-specific expression, multiple promoters, and regulatory elements. Myers SJ, Peters J, Huang Y, Comer MB, Barthel F, Dingledine R. J Neurosci. 1998 Sep 1;18(17):6723-39. doi: 10.1523/JNEUROSCI.18-17-06723.1998. PMID: 9712644 42 Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. Wong LM, Myers SJ, Tsou CL, Gosling J, Arai H, Charo IF. J Biol Chem. 1997 Jan 10;272(2):1038-45. doi:10.1074/jbc.272.2.1038. 6 PMID: 8995400 43 Signal transduction and ligand specificity of the human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells. Myers SJ, Wong LM, Charo IF. J Biol Chem. 1995 Mar 17;270(11):578692. doi: 10.1074/jbc.270.11.5786. PMID: 7890708 44 Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2752-6. doi: 10.1073/pnas.91.7.2752. PMID: 8146186 Patents (Published, Provisional, Abandoned) 1. GluN2B-Subunit Selective Antagonists of the N-methyl-D-Aspartate Receptor with Enhanced Potency at Acidic pH. Liotta DC, Traynelis SF, Wilson L, Tahirovic YA, Menaldino D, Myers SJ, and Poornachary K. Application 63/240,125, 09/02/2021. 2. NMDA Receptor antagonists for neuroprotection. Liotta DC, Snyder JP, Traynelis SF, Wilson L, Mosley C, Dingledine R, Myers SJ, and Tahirovic YA. PCT/US2008/068843, Pub. No.WO/2009/006437 3. Compounds for the treatment of neurological disorders, Ruppa PKB, Myers SJ. US2012/0302543 A1. 4. Compounds for the treatment of neurological disorders, Ruppa PKB, Myers Scott J., Koszalka GW. PCT/US2013/040408, Pub. No. WO/2013/170072 A2 5. Compounds for the treatment of neurological disorders, Menaldino DS, Koszalka GW, Ruppa PKB, Myers SJ. US Non-Provisional Patent Application No. 14/210771 Filing date March 14, 2014 6. Compounds for the treatment of neurological disorders, Ruppa PKB, Myers SJ, Koszalka GW, Lowe III JA, US Provisional Patent Application 61/968,322, Filing date March 20, 2014 7